WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010144038) MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/144038    International Application No.:    PCT/SE2010/050626
Publication Date: 16.12.2010 International Filing Date: 07.06.2010
IPC:
C07K 7/06 (2006.01), A61K 38/08 (2006.01), A61P 3/04 (2006.01)
Applicants: ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE) (For All Designated States Except US).
DODD, John H. [US/US]; (US) (For US Only).
SHI, Yi-Qun [US/US]; (US) (For US Only).
YANG, Wei [US/US]; (US) (For US Only)
Inventors: DODD, John H.; (US).
SHI, Yi-Qun; (US).
YANG, Wei; (US)
Agent: ASTRAZENECA INTELLECTUAL PROPERTY; AstraZeneca AB S-151 85 Södertälje (SE)
Priority Data:
61/184,932 08.06.2009 US
Title (EN) MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES
(FR) PEPTIDES SPÉCIFIQUES DU RÉCEPTEUR DE MÉLANOCORTINE
Abstract: front page image
(EN)The invention relates to melanocortin receptor-specific cyclic peptides of Formula (I) or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4a, R4b, R4C, R5, x and y are as defined in the specification. These compounds are particularly useful in the treatments of energy homeostasis and metabolism related (e.g. diabetes), food intake related and/or energy balance and body weight related diseases, disorders and/or conditions, including obesity, overweight and diseases, disorders and/or conditions associated with obesity and/or overweight, such as type 2 diabetes and metabolic syndrome.
(FR)L'invention concerne des peptides cycliques spécifiques du récepteur de mélanocortine de formule (I) ou un de leurs sels pharmaceutiquement acceptables, dans laquelle R1, R2, R3, R4a, R4b, R4C, R5, x et y sont tels que définis dans la description. Ces composés sont particulièrement utiles pour le traitement de maladies, troubles et/ou états associés à l'homéostasie énergétique et au métabolisme (p. ex. diabète), à la consommation d'aliments et/ou à l'équilibre énergétique et au poids corporel, y compris l'obésité, le surpoids et les maladies, troubles et/ou états associés à l'obésité et/ou au surpoids, tels que le diabète de type 2 et le syndrome métabolique.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)